Please assess the completion status of the following clinical trial:

Trial Title: Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* receiving stable dose of oral ropinirole or pramipexole whose symptoms are not optimally controlled or whose oral dopamine agonist titration regimen was truncated due to intolerability:~* 1) Minimum dose of agonist will be 6 mg/day for ropinirole and 1.0 mg/day for pramipexole~* 2) Stable dopamine agonist treatment must have been ongoing for ≥ 30 days, no longer than 5 years preceding baseline~* Males and females. Women of childbearing potential must agree to practice an acceptable method of birth control.~* Idiopathic Parkinson Disease confirmed at baseline by presence of at least 2 cardinal signs (resting tremor, bradykinesia, rigidity), w/o other known or suspected cause of Parkinsonism~* Hoehn \& Yahr \> 1 (symptoms on only one side of the body) with treatment and \< 3 (mild to moderate bilateral disease; some postural instability; physically independent).~* Dopamine agonist dose must be stable for ≥30 days preceding the baseline visit.~* For patients who are receiving amantadine or anticholinergics, the dose must have been stable for ≥30 days prior to screening.~* Medically stable outpatients (Investigator's judgment).~Exclusion Criteria:~* receive rasagiline or other monoamine oxidase (MAO) inhibitors 60 days preceding baseline~* receive levodopa \> 21 consecutive days within 90 days prior baseline~* moderate to severe motor fluctuations~* hepatic impairment~* investigational medications 30 days preceding baseline~* dopamine agonist use \> 5 years prior to baseline~* major depression as defined by Beck Depression Inventory (BDI) short form score greater than 14~* significant cognitive impairment as defined by Mini-Mental State Exam (MMSE) score less than 26.~* impulse control disorder (ICD) based on the Questionnaire for Impulsive-compulsive Disorders in Parkinson's Disease form (QUIP).~* pregnant or lactating or planning on becoming pregnant in the next 18 weeks~* uncontrolled hypertension. Patients whose hypertension is controlled with medications are eligible.~* Concomitant monoamine oxidase (MAO) inhibitors or medicines contraindicated w/ MAO inhibitors not allowed

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rasagiline 1 mg (Type: EXPERIMENTAL): Participants took a 1 mg rasagiline tablet orally each day for 18 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants took a matching placebo tablet once daily for 18 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).